Maxine Lam

Maxine Lam

Auto-generated profile, based on publicly available information

Maxine Lam

Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A∗STAR), 61 Biopolis Drive, Singapore, 138673, Republic of Singapore

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TWTom P. J. Wyatt
Tom P. J. Wyatt
AHAndrew R. Harris
Andrew R. Harris
MLMaxine Lam
Maxine Lam
QCQian Cheng
Qian Cheng
JBJulien Bellis
Julien Bellis
BBBuzz Baum
Buzz Baum
Significance: Animal cells undergo a remarkable series of shape changes as they pass through mitosis and divide. In an epithelial tissue, the impact of these morphogenetic processes depends strongly on the orientation of division. However, the cues orienting divisions remain poorly understood. Here, we combine live imaging and mechanical perturbations with computational modeling to investigate the effects of shape changes accompanying mitosis and division in stretched monolayers in the absence of neighbor exchange. We show that divisions orient with the long cell axis rather than with the stress direction, and show how oriented divisions contribute to the restoration of cell packing and stress relaxation. In doing so, we identify a clear role for oriented cell division in morphogenetically active tissues.

1 March 2012 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
RJRebecca A. Johnson
Rebecca A. Johnson
MLMaxine Lam
Maxine Lam
APAntonio M. Punzo
Antonio M. Punzo
HLHongda Li
Hongda Li
BLBenjamin R. Lin
Benjamin R. Lin
QCQiang Chang
Qiang Chang
Rett syndrome (RTT), caused by mutations in the methyl-CpG binding protein 2 gene (MECP2), is a debilitating autism spectrum developmental disorder predominantly affecting females. Mecp2 mutant mice have reduced levels of brain-derived neurotrophic factor (BDNF) in the brain; conditional deletion and overexpression of BDNF in the brain accelerates and slows, respectively, disease progression in Mecp2 mutant mice. Thus we tested the hypothesis that 7,8-dihydroxyflavone (7,8-DHF), a small molecule reported to activate the high affinity BDNF receptor (TrkB) in the CNS, would attenuate disease progression in Mecp2 mutant mice. Following weaning, 7,8-DHF was administered in drinking water throughout life. Treated mutant mice lived significantly longer compared with untreated mutant littermates (80 ± 4 and 66 ± 2 days, respectively). 7,8-DHF delayed body weight loss, increased neuronal nuclei size and enhanced voluntary locomotor (running wheel) distance in Mecp2 mutant mice. In addition, administration of 7,8-DHF partially improved breathing pattern irregularities and returned tidal volumes to near wild-type levels. Thus although the specific mechanisms are not completely known, 7,8-DHF appears to reduce disease symptoms in Mecp2 mutant mice and may have potential as a therapeutic treatment for RTT patients.

30 August 2023 in Small
Verified
Journal Article
Open access
MLMaxine Sy Lam
Maxine Sy Lam
JAJoey Jy Aw
Joey Jy Aw
DTDamien Tan
Damien Tan
RVRagavi Vijayakumar
Ragavi Vijayakumar
HLHui Yi Grace Lim
Hui Yi Grace Lim
APAndrea Pavesi
Andrea Pavesi
Glioblastoma (GBM) is the most common primary malignant brain cancer in adults with a dismal prognosis. Temozolomide (TMZ) is the first‐in‐line chemotherapeutic; however, resistance is frequent and multifactorial. While many molecular and genetic factors have been linked to TMZ resistance, the role of the solid tumor morphology and the tumor microenvironment, particularly the blood‐brain barrier (BBB), is unknown. Here, the authors investigate these using a complex in vitro model for GBM and its surrounding BBB. The model recapitulates important clinical features such as a dense tumor core with tumor cells that invade along the perivascular space; and a perfusable BBB with a physiological permeability and morphology that is altered in the presence of a tumor spheroid. It is demonstrated that TMZ sensitivity decreases with increasing cancer cell spatial organization, and that the BBB can contribute to TMZ resistance. Proteomic analysis with next‐generation low volume sample workflows of these cultured microtissues revealed potential clinically relevant proteins involved in tumor aggressiveness and TMZ resistance, demonstrating the utility of complex in vitro models for interrogating the tumor microenvironment and therapy validation.

15 June 2020 in Molecular Biology of the Cell
Verified
Journal Article
Open access
MLMaxine S. Y. Lam
Maxine S. Y. Lam
ALAna Lisica
Ana Lisica
NRNitya Ramkumar
Nitya Ramkumar
GHGinger Hunter
Ginger Hunter
YMYanlan Mao
Yanlan Mao
BBBuzz Baum
Buzz Baum
By studying the dynamics of spindle orientation in mechanically distinct regions of an epithelium, this article reveals a role for isotropic tension in aiding accurate alignment of the spindle with the long cell axis.

9 February 2025 in Biomaterials
Verified
Journal Article
Open access
JVJyothsna Vasudevan
Jyothsna Vasudevan
RVRagavi Vijayakumar
Ragavi Vijayakumar
JRJose Antonio Reales-Calderon
Jose Antonio Reales-Calderon
MLMaxine S.Y. Lam
Maxine S.Y. Lam
JOJin Rong Ow
Jin Rong Ow
APAndrea Pavesi
Andrea Pavesi
The complex tumor microenvironment (TME) presents significant challenges to the development of effective therapies against solid tumors, highlighting the need for advanced in vitro models that better recapitulate TME biology. To address this, we developed a vascularized human liver tumor model using a microfluidic platform, designed to test both drug and cell-based therapies. This model mimics critical tumorigenic features such as hypoxia, extracellular matrix (ECM), and perfusable vascular networks. Intravascular administration of Sorafenib demonstrated its ability to disrupt vascular structures significantly, while eliciting heterogeneous responses in two distinct liver tumor cell lines, HepG2 and Hep3b. Furthermore, treatment with engineered T-cells revealed that the tumor vasculature impeded T-cell infiltration into the tumor core but preserved their cytotoxic capacity, albeit with reduced exhaustion levels. Cytokine analysis and spatial profiling of vascularized tumor samples identified proinflammatory factors that may enhance T-cell-mediated antitumor responses. By capturing key TME characteristics, this microfluidic platform provides a powerful tool enabling detailed investigation of tumor-immune and tumor-vascular interactions. Its versatility could serve as a promising bridge between preclinical studies and clinical testing, offering opportunities for developing and optimizing personalized therapeutic strategies for solid tumors.

4 October 2021 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
MLMaxine Lam
Maxine Lam
JRJose Antonio Reales-Calderon
Jose Antonio Reales-Calderon
JOJin Rong Ow
Jin Rong Ow
GAGiulia Adriani
Giulia Adriani
APAndrea Pavesi
Andrea Pavesi
Despite diagnostic and therapeutic advances, liver cancer kills more than 18 million people every year worldwide, urging new strategies to model the disease and to improve the current therapeutic options. In vitro tumor models of human cancer continue to evolve, and they represent an important screening tool. However, there is a tremendous need to improve the physiological relevance and reliability of these in vitro models to fulfill today's research requirements for better understanding of cancer progression and treatment options at different stages of the disease. This review describes the hepatocellular carcinoma microenvironmental characteristics and illustrates the current immunotherapy strategy to fight the disease. Moreover, we present a recent collection of 2D and 3D in vitro liver cancer models and address the next generation of in vitro systems recapitulating the tumor microenvironment complexity in more detail.